Entry created on 1 July 2019 (Revision 1.0) Annotator: Rita Pancsa; Orsolya Kovács
Basic protein information
Accession P24928
Common name RPB1
Gene POLR2A
Organism Homo sapiens
Uniprot name DNA-directed RNA polymerase II subunit RPB1
Basic LLPS information
Organelle RNA polymerase II, holoenzyme; POLII clusters
Type of experimental evidence
Protein region(s) mediating LLPS
1593
-
1960
C-terminal tail with 52 heptade repeats of YSPTSPS
Based on the experimental results of the following publication: 30127355
Molecular features viewer
PDB structures
Extended LLPS information
Functional description
The largest subunit of Pol II, RPB1, contains a C-terminal low-complexity domain, CTD, that is critical for pre-mRNA synthesis and co-transcriptional processing. The CTD is conserved from humans to fungi, but differs in the number of its heptapeptide repeats, with the consensus sequence YSPTSPS. Truncating the CTD of RPB1 in S. cerevisiae to fewer than 13 repeats leads to growth defects, and a minimum of eight repeats is required for yeast viability. The CTD serves as a platform for assembly of factors that regulate transcription initiation, elongation, termination and mRNA processing. Assembly of the preinitiation complex at Pol II promoters requires an unphosphorylated CTD and that subsequent CTD phosphorylation at S5 CTD residues by the cyclin-dependent kinase 7 (CDK7) in transcription factor IIH (TFIIH) stimulates the transition of Pol II into active elongation. Therefore, phosphorylation at S5 is incompatible with CTD phase separation and transfers the CTD from the highly concentrated state within droplets to the dispersed pool (PMID:30127355). Phase separated condensates formed by the LC domains of FUS, EWS and TAF15 when they are translocated onto a variety of different DNA-binding domains in oncogenic fusion proteins directly bind the C-terminal domain (CTD) of RNA polymerase II in a manner reversible by phosphorylation of the iterated, heptad repeats of the CTD (PMID:24267890, PMID:28945358). Mediator and Pol II, both of which can form small transient and large stable clusters in living embryonic stem cells, are co-localized in the stable clusters, which associate with chromatin, have properties of phase-separated condensates, and are sensitive to transcriptional inhibitors. Large clusters of Mediator, recruited by transcription factors at large or clustered enhancer elements probably interact with large Pol II clusters in transcriptional condensates in vivo (PMID:29930094).
Literature supporting the LLPS: 29849146, 29930094, 30127355
Functional class of membraneless organelle: activation/nucleation/signal amplification/bioreactor
Binding partners (at biological protein concentrations)
N/A
Type of RNA(s) required/used for the LLPS at biological protein concentrations
Not required.
Molecular interaction types contributing to LLPS
Not known
Determinants of phase separation and droplet properties
1) phosphorylation state 2) valency of CTD
Membrane cluster No
Partner-dependent No
RNA-dependent No
PTM required No
Domain-motif interactions No
Discrete oligomerization No
Regulation and disease
Post-translational modifications affecting LLPS
Position Residue PTM Effect Reference Modifying enzyme Notes
Isoforms known to affect LLPS
Isoform Effect Reference
All known isoforms containing sequence changes in the LLPS region(s)
Position type Isoform names from UniProt
Disease mutations affecting LLPS
Mutation dbSNP Disease OMIM Effect Reference Notes
Experimental information
Experimental techniques applied to prove/investigate LLPS
In vitro differential interference contrast (DIC) microscopy revealed the formation of micrometer-sized droplets (particle size and count) at a concentration of 20 μM MBP-fused human Pol II CTD in the presence of 5–10% of dextran. Fluorescence microscopy demonstrated that MBP-hCTD molecules were strongly concentrated within the droplet interior compared to the surrounding milieu (protein localization). At higher dextran concentration (16%), droplets could be detected at a concentration of 5 μM MBP-hCTD and the number of droplets increased with increasing protein concentration. hCTD also underwent LLPS after cleavage of the maltose-binding protein (MBP) tag, and droplet formation was robust against changes in ionic strength and against incubation of the sample for 1 h at different temperatures (particle size and count by microscopy). As expected for such interactions, liquid phase separation of yCTD and hCTD was counteracted by addition of 5–10% 1,6-hexanediol. The length of CTD influences the stability and dynamics of LLPS droplets, with a longer CTD (mutation) leading to stronger CTD–CTD interactions and less dynamic droplets (morphology), and also affects POLII clustering (particle size and count by microscopy). Using two engineered human cell lines that express a fluorescent Dendra2-tagged version of RPB1 (creation of a fusion protein), cells with the truncated, yeast-like CTD (25R) showed less Pol II clustering in vivo (particle size and count by microscopy) than cells with full-length human CTD (52R). CDK7-phosphorylated hCTD was no longer able to form droplets. In addition, phosphorylation of preformed hCTD droplets by human CDK7 caused gradual shrinking and ultimately disappearance of hCTD droplets (particle size and count by microscopy) (PMID:30127355).
Experimental observations supporting the liquid material state of the condensate
dynamic movement/reorganization of molecules within the droplet (PMID:30127355) morphological traits (PMID:30127355) sensitivity to 1,6-hexanediol (PMID:30127355)